Phase I Dose Escalation Study of Bortezomib in Combination with Lenalidomide in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

We conducted a phase I dose escalation study to determine the maximal tolerated dose of bortezomib that could be combined with standard dose lenalidomide in patients with MDS or AML. Treatment consisted of bortezomib (IV) on Days 1, 4, 8, and 11 and lenalidomide 10 mg daily (PO) days 1–21 in 28 day...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Attar, Eyal C., Amrein, Philip C., Fraser, James W., Fathi, Amir, McAfee, Steven, Wadleigh, Martha, DeAngleo, Daniel J., Steensma, David, Stone, Richard M., Foster, Julia, Neuberg, Donna, Ballen, Karen K.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3969839/
https://ncbi.nlm.nih.gov/pubmed/23773898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.05.011
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki